Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024

HOLON, Israel, March 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) annual meeting on April 5-11, 2024, in San Diego, California. "It is exciting that the progress we have made to potentially addre ...